Sponsors (9)
Official title: Reauthorize certain programs that provide for opioid use disorder prevention, treatment, and recovery, and for other purposes.
Introduced June 18, 2025 by Bill Cassidy · Last progress June 18, 2025
The bill provides sustained, expanded funding and broader prevention, treatment, and workforce supports to address overdoses and behavioral health needs, but does so at higher federal cost while introducing privacy, administrative, implementation, and some access‑risk tradeoffs that will need careful mitigation.
State, Tribal, and local grantees (and the communities they serve) gain predictable multi-year federal funding authorizations (FY2026–2030) that stabilize and sustain overdose-prevention, recovery, and behavioral-health programs.
Communities and public health agencies can detect and respond earlier to overdoses because prevention and surveillance are expanded to cover all overdose-causing substances (including fentanyl, xylazine) and permit evidence-based wastewater and other innovative surveillance when privacy‑protective and actionable.
Behavioral-health workforce capacity is strengthened through higher loan-repayment funding, reauthorized training grants, and expanded support for peer and tribal programs, improving recruitment, retention, and service quality in high-need areas.
Taxpayers face materially higher federal spending because multiple programs are reauthorized with increased annual funding levels, raising budgetary costs without guaranteed programmatic outcomes.
Expanded surveillance authorities (including wastewater and other novel monitoring) raise privacy and civil‑liberties concerns for communities if data use, de‑identification, or safeguards are not clear and strictly enforced.
New reporting, mandated reviews, program requirements, and guidance updates impose significant administrative and compliance burdens on States, Tribes, grantees, and HHS staff, potentially diverting resources from direct service delivery.
Based on analysis of 8 sections of legislative text.
Reauthorizes and increases funding for federal substance-use and behavioral health programs, broadens overdose surveillance to all overdose-causing substances, expands treatment and workforce supports, and adjusts controlled-substance delivery rules.
Updates and reauthorizes multiple federal public health programs focused on substance use, overdose prevention, and behavioral health. It shifts some programs from opioid-specific focus to all substances that cause overdose, increases and specifies funding authorization amounts for 2026–2030, expands surveillance and monitoring authorities (including wastewater surveillance when supported by evidence), and strengthens treatment, training, and recovery support activities — including larger grants for residential treatment for pregnant and postpartum women and expanded loan repayment for behavioral health clinicians. The bill also makes targeted changes to controlled-substance and pharmacy delivery rules, directs HHS to review certain programs and data (including buprenorphine–naloxone product data), creates a time-limited regional technical assistance center with a required multi-year evaluation, and requires multiple reports to Congressional committees on program outcomes and guidance updates.